The effect of adiponectin gene polymorphism on the severity of metabolic disorders and some liver parameters in patients with non-alcoholic fatty liver disease in combination with hypertension

K.О. Prosolenko

Kharkiv National Medical University.

The aim of the work was to study the relationship of the genetic polymorphism of the G276T marker of the ADIPOQ gene with the severity of metabolic disorders and changes in some liver indices with comorbidity of hypertension (Н) and non-alcoholic fatty liver disease (NAFLD).

The object of the study was 116 patients with comorbidity of NAFLD and stage II Н, 2 degrees. The average age of the patients was 49.11 ± 9.95 years. The control group consisted of 20 healthy individuals of the same age category of male and female. Blood biochemical parameters were determined according to standard methods and the contents were studied: aminotransferases, gamma-glutamyltranspeptidase, glucose, glycosylated hemoglobin, insulin, adiponectin. The HOMA index was also determined. Based on the polymer chain reaction data, the ADIPOQ genetic polymorphism was determined.

Three ADIPOQ genotypes (G/G, G/T and T/T) were identified by G276T polymorphism. According to our data, the presence of the T allele of the G276T polymorphic marker of the ADIPOQ gene is associated with the development of comorbidity of Н and NAFLD. In patients with comorbidity Н and NAFLD G/T or T/T genotypes, more pronounced disorders of carbohydrate and lipid metabolism are characteristic than with the G/G genotype. The T allele of the G276T polymorphic marker of the ADIPOQ gene is associated with the development of more significant liver damage in patients with comorbidity of Н and NAFLD, which is confirmed by significantly higher rates of hepatic cytolysis.

Key Words: non-alcoholic fatty liver disease, hypertension, adiponectin gene polymorphism, metabolic disorders, markers of liver damage.


For citing:

1. Просоленко, К.О. Вплив поліморфізму гена адипонектину на тяжкість метаболічних порушень та деякі печінкові показники у пацієнтів з неалкогольною жировою хворобою печінки у поєднанні з гіпертонічною хворобою // Східноєвропейський журнал внутрішньої та сімейної медицини. – 2020. – № 1. – С. 95-98. doi: 10.15407/internalmed2020.01.095

2. Prosolenko KО. [The effect of adiponectin gene polymorphism on the severity of metabolic disorders and some liver parameters in patients with nonalcoholic fatty liver disease in combination with hypertension]. Shidnoevr. z. vnutr. simejnoi med. 2020;1:95-98. doi: 10.15407/internalmed2020.01.095. Ukrainian.


1. Hashemi M, Bojd HH, Nasab EE, Bahari A, Hashemzehi NA, Shafieipour S, Narouie B, Taheri M, Ghavami S Association of Adiponectin rs1501299 and rs266729 Gene Polymorphisms with Nonalcoholic Fatty Liver Disease Hepat Mon. 2013;13(5):e9527. doi: 10.5812/hepatmon.9527

2. Iminova DA, Alyavi AL, Sobirova GN Association of Gene Polymorphism Adipoq +276 (G/T) with Surrogatic Markers of the Increased Fat Content in the Liver. American Journal of Medicine and Medical Sciences. 2019;9(12):464-466. DOI: 10.5923/j.ajmms.20190912.03

3. Lin CH, Ho CY, Liu CS. Influence of Adiponectin Gene Polymorphisms on Adiponectin Serum Level and Insulin Resistance Index in Taiwanese Metabolic Syndrome Patients. Chin J Physiol. 2012;55(6):405-411.

4. Liu J, Xing J, Wang B, Wei C, Yang R, Zhu Y, Qiu H Correlation Between Adiponectin Gene rs1501299 Polymorphism and Nonalcoholic Fatty Liver Disease Susceptibility: A Systematic Review and Meta-Analysis. Med Sci Monit. 2019;25:1078-1086. doi: 10.12659/MSM.912737.

5. Mohseni F, Moghbelinejad S, Najafipour R Major Components of Metabolic Parameters and Nutritional Intakes in Different Genotypes of Adiponectin +276 G>T Gene Polymorphism in Non-Diabetes and Non-Alcoholic Iranian Fatty Liver Patients. Avicenna J Med Biotechnol. 2017;9(3):155-161. PMCID: PMC5501145

6. Tokushige K, Hashimoto E, Noto H, Yatsuji S, Taniai M, Torii N, Shiratori K Influence of adiponectin gene polymorphisms in Japanese patients with non-alcoholic fatty liver disease. Journal of Gastroenterology. 2009;44(9):976-982.

7. Semple RK How does insulin resistance arise, and how does it cause disease? Human genetic lessons. European Journal of Endocrinology. 2016;174:R209-R223.

8. Sheng T, Yang K. Adiponectin and its association with insulin resistance and type 2 diabetes. J Genet Genom. 2008;35:321-326.

9. Shalimova A, Fadieienko G, Kolesnikova O, Isayeva A, Zlatkina V, Nemtsova V, Prosolenko K, Psarova V, Kyrychenko N, Kochuieva M. The Role of Genetic Polymorphism in the Formation of Arterial Hypertension, Type 2 Diabetes and their Comorbidity. Current Pharmaceutical Design. 2019;25(3):218-227.

10. Siitonen N, Pulkkinen L, Lindström J, Kolehmainen M, Eriksson J, Venojärvi M, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Tuomilehto J, Uusitupa M. Association of ADIPOQ gene variants with body weight, type 2 diabetes and serum adiponectin concentrations: the Finnish Diabetes Prevention Study. BMC Medical Genetics. 2011;10(1):12-15.

11. Wang BF, Wang Y, Ao R, Tong J, Wang BY. AdipoQT45 G and G276 TPolymorphisms and Susceptibility to Nonalcoholic Fatty Liver Disease Among Asian Populations: A Meta-Analysis and Meta-Regression. Journal of Clinical Laboratory Analysis. 2014;30(1):47-57.

12. Whitehead J, Richards A, Hickman I, Macdonald G, Prins J. Adiponectin – a key adipokine in the metabolic syndrome. Diabetes, Obesity and Metabolism. 2006;8(3):264-280.